Learn how frameworks like Solid, Svelte, and Angular are using the Signals pattern to deliver reactive state without the ...

Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...

If you’ve been diagnosed with transthyretin cardiac amyloidosis (ATTR-CM), you may be debating between two treatments: transthyretin (TTR) stabilizers and gene silencers. Both drug families are ...

Patients with ATTR-CM who experienced outpatient worsening heart failure had a 2.5-fold increased risk of mortality compared with those who did not. Outpatient worsening heart failure is an ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...

ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...

Alnylam’s closely watched launch of its rare disease drug Amvuttra continued to outpace Wall Street expectations. Riding its March expansion into the heart condition of transthyretin amyloid ...

Intellia Therapeutics has temporarily paused dosing and screening in a pair of phase 3 trials in response to a liver safety signal. Shares in Intellia fell 44% to $14.34 in early trading Monday. The ...